Johnson & Johnson's (JNJ) 'AAA' dividend safety makes it a candidate for investors with a low tolerance for risk who are looking for a reliable source of income. Having increased its dividend for 58 consecutive years, JNJ meets the Dividend King criteria; a Dividend King is an S&P 500 company with a market capitalization [...]
Johnson & Johnson (JNJ) released Q2 2019 results on July 16, 2019. Although there is significant overhang from the 'talc' and 'opioid' legal issues I anticipate that any penalties JNJ does incur will be far less than those sought by the plaintiffs. I view JNJ as being reasonably valued and would acquire additional shares [...]
Reuters has recently published a story indicating that Johnson & Johnson (JNJ) has known internally about the presence of asbestos in its talcum powder for decades. This is not a new revelation as a review of JNJ's 10-K reports from several prior years discloses the talc issue under 'Legal Proceedings'. There are currently ~9,000 [...]
Summary Reuters has recently published a story that JNJ has known internally about the presence of asbestos in its talcum powder for decades. Regardless of whether investors feel this is ‘old news’ or not, the fact remains that there are roughly 9,000 – 10,000 pending talc related cases. JNJ is currently appealing a case [...]
Summary JNJ warrants a position in your investment portfolio because of its financial strength, historical performance, and future growth prospects. It has been and will remain a long-term hold in our retirement accounts and in the FFJ Portfolio. JNJ is 1 of only 2 companies rated AAA by Moody’s which provides me peace of mind [...]
